Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6910

1.

Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance and Healthcare Utilization in Patients with Inflammatory Bowel Disease.

Chablani SV, Ramos-Rivers C, Binion DG, Szigethy E.

Dig Dis Sci. 2018 Jul 19. doi: 10.1007/s10620-018-5194-1. [Epub ahead of print] No abstract available.

PMID:
30022454
3.

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients with Ulcerative Colitis.

Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C.

Clin Gastroenterol Hepatol. 2018 Jul 13. pii: S1542-3565(18)30709-2. doi: 10.1016/j.cgh.2018.07.009. [Epub ahead of print]

PMID:
30012431
4.

Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?

Mason A, Holmes C, Edwards CJ.

Autoimmun Rev. 2018 Jul 10. pii: S1568-9972(18)30161-7. doi: 10.1016/j.autrev.2018.04.001. [Epub ahead of print] Review.

PMID:
30005856
5.

Cecropin A Modulates Tight Junction-Related Protein Expression and Enhances the Barrier Function of Porcine Intestinal Epithelial Cells by Suppressing the MEK/ERK Pathway.

Zhai Z, Ni X, Jin C, Ren W, Li J, Deng J, Deng B, Yin Y.

Int J Mol Sci. 2018 Jul 2;19(7). pii: E1941. doi: 10.3390/ijms19071941.

6.

Recent trends (2016-2017) in the treatment of inflammatory bowel disease.

Masaki T, Kishiki T, Kojima K, Asou N, Beniya A, Matsuoka H.

Ann Gastroenterol Surg. 2018 Jun 2;2(4):282-288. doi: 10.1002/ags3.12177. eCollection 2018 Jul. Review.

7.

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).

Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM.

BMJ Open Gastroenterol. 2018 Jul 7;5(1):e000212. doi: 10.1136/bmjgast-2018-000212. eCollection 2018.

8.

Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease.

Bernardes C, Russo P, Carvalho D, Saiote J, Ramos J.

GE Port J Gastroenterol. 2018 Jun;25(4):175-178. doi: 10.1159/000484440. Epub 2017 Nov 18.

9.

Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends.

Mijan MA, Lim BO.

World J Gastroenterol. 2018 Jul 7;24(25):2673-2685. doi: 10.3748/wjg.v24.i25.2673. Review.

10.

Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome.

Jacob N, Jacobs JP, Kumagai K, Ha CWY, Kanazawa Y, Lagishetty V, Altmayer K, Hamill AM, Von Arx A, Sartor RB, Devkota S, Braun J, Michelsen KS, Targan SR, Shih DQ.

Mucosal Immunol. 2018 Jul 9. doi: 10.1038/s41385-018-0055-y. [Epub ahead of print]

PMID:
29988118
11.

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.

Guilcher K, Fournier N, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study.

Eur J Gastroenterol Hepatol. 2018 Jul 5. doi: 10.1097/MEG.0000000000001197. [Epub ahead of print]

PMID:
29985208
12.

Gelatin versus its two major degradation products, prolyl-hydroxyproline and glycine, as supportive therapy in experimental colitis in mice.

Zhu S, Huang M, Feng G, Miao Y, Wu H, Zeng M, Lo YM.

Food Sci Nutr. 2018 Apr 16;6(4):1023-1031. doi: 10.1002/fsn3.639. eCollection 2018 Jun.

13.

Frequency of Herpes Zoster Vaccination Among Inflammatory Bowel Disease Patients.

Khan N, Trivedi C, Kavani H, Lewis J, Yang YX.

Inflamm Bowel Dis. 2018 Jul 5. doi: 10.1093/ibd/izy232. [Epub ahead of print]

PMID:
29982646
14.

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis.

Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum L.

Gastroenterology. 2018 Jul 4. pii: S0016-5085(18)34719-X. doi: 10.1053/j.gastro.2018.06.077. [Epub ahead of print]

15.

Therapeutic Effect of Amomum villosum on Inflammatory Bowel Disease in Rats.

Chen Z, Ni W, Yang C, Zhang T, Lu S, Zhao R, Mao X, Yu J.

Front Pharmacol. 2018 Jun 20;9:639. doi: 10.3389/fphar.2018.00639. eCollection 2018.

16.

Protective Effect of Pure Sour Cherry Anthocyanin Extract on Cytokine-Induced Inflammatory Caco-2 Monolayers.

Le Phuong Nguyen T, Fenyvesi F, Remenyik J, Homoki JR, Gogolák P, Bácskay I, Fehér P, Ujhelyi Z, Vasvári G, Vecsernyés M, Váradi J.

Nutrients. 2018 Jul 3;10(7). pii: E861. doi: 10.3390/nu10070861.

17.

Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.

Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A.

Expert Opin Biol Ther. 2018 Jul 16:1-10. doi: 10.1080/14712598.2018.1495193. [Epub ahead of print]

PMID:
29962245
18.

Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).

Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, Quantin C, Bardou M.

Am J Gastroenterol. 2018 Jul 2. doi: 10.1038/s41395-018-0176-7. [Epub ahead of print]

PMID:
29961771
19.

Is Curcumin a Possibility to Treat Inflammatory Bowel Diseases?

Mazieiro R, Frizon RR, Barbalho SM, Goulart RA.

J Med Food. 2018 Jun 29. doi: 10.1089/jmf.2017.0146. [Epub ahead of print]

PMID:
29957091
20.

How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease.

Naviglio S, Giuffrida P, Stocco G, Lenti MV, Ventura A, Corazza GR, Di Sabatino A.

Expert Rev Gastroenterol Hepatol. 2018 Jul 6:1-14. doi: 10.1080/17474124.2018.1494573. [Epub ahead of print]

PMID:
29957083

Supplemental Content

Loading ...
Support Center